PR Newswire
NEW YORK, Dec. 6, 2023
NEW YORK, Dec. 6, 2023 /PRNewswire/ -- Julie & Holleman LLP, a nationally recognized shareholder rights law firm, is investigating the proposed $45 per share sale of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. The firm has already identified potential conflicts of interest related to the merger.
For a free consultation and to learn about our investigation, click here or visit: https://julieholleman.com/?p=3218
On December 6, 2023, Cerevel announced that it had entered into an agreement for the company to be acquired by AbbVie for $45 per share, or a total of $8.7 billion. The transaction, which is subject to shareholder approval, is expected to close in mid-2024.
Julie & Holleman, whose attorneys have helped secure hundreds of millions of dollars for shareholders, is concerned about potential conflicts, including related to Cerevel's largest shareholder, Bain Capital.
If you would like more information about our investigation, please contact W. Scott Holleman at [email protected] or (917) 325-3798, or submit your information by clicking here.
Julie & Holleman is a boutique law firm that focuses on shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations. The firm's attorneys litigate in state and federal courts across the nation and have helped secure hundreds of millions of dollars for aggrieved companies and their shareholders. For more information about the firm, please visit https://www.julieholleman.com/. This notice may constitute attorney advertising. Past results do not guarantee future outcomes.
CONTACT INFORMATION
Julie & Holleman LLP
W. Scott Holleman, Esq.
157 East 86th Street
4th Floor
New York, NY 10028
(929) 415-1020
www.julieholleman.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cere-merger-announcement-julie--holleman-llp-announces-investigation-into-potential-claims-regarding-abbvies-proposed-acquisition-of-cerevel-therapeutics-302008308.html
SOURCE Julie & Holleman LLP
